Evidence map›Paper›PMID 42292330›Full record

ArticleFrontiers in neuroscience2026

Vascular endothelial growth factor receptor-1 (VEGFR-1) knock-down is protective against hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril -induced neuronal cell death: implications in AD pathogenesis.

Ramcharan Singh Angom, Zonghua Li, Hari Krishnareddy Rachamala, Monica Castanedes-Casey, Tanmay Kulkarni, Trisha Chakravarty, Shamit Dutta, Enfeng Wang, Dennis Dickson, Debabrata Mukhopadhyay and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ramcharan Singh AngomDepartment of Biochemistry and Molecular Biology, Mayo Clinic Florida, Jacksonville, FL, United States.
Zonghua LiDepartment of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, United States.
Hari Krishnareddy RachamalaDepartment of Biochemistry and Molecular Biology, Mayo Clinic Florida, Jacksonville, FL, United States.
Monica Castanedes-CaseyDepartment of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, United States.
Tanmay KulkarniDepartment of Biochemistry and Molecular Biology, Mayo Clinic Florida, Jacksonville, FL, United States.
Trisha ChakravartyDepartment of Biochemistry and Molecular Biology, Mayo Clinic Florida, Jacksonville, FL, United States.
Shamit DuttaDepartment of Biochemistry and Molecular Biology, Mayo Clinic Florida, Jacksonville, FL, United States.
Enfeng WangDepartment of Biochemistry and Molecular Biology, Mayo Clinic Florida, Jacksonville, FL, United States.
Dennis DicksonDepartment of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, United States.
Debabrata MukhopadhyayDepartment of Biochemistry and Molecular Biology, Mayo Clinic Florida, Jacksonville, FL, United States.
Pritam DasDepartment of Biochemistry and Molecular Biology, Mayo Clinic Florida, Jacksonville, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Recent transcriptome analysis has demonstrated increased expression of Vascular Endothelial Growth Factor receptor-1 (VEGFR-1/FLT1) and in AD brain. Increased expression of VEGFR1 and its ligand VEGFB were associated with a more rapid rate of cognitive decline, providing evidence of a potential link between increased VEGFR-1 expression in AD pathogenesis. In this study, we explored the potential role of VEGFR-1 expression in neurons on AD pathology. Methods: To confirm VEGFR1 expression in AD brains, we first performed immunostaining in AD brain sections (AD - Braak stage V-VI, and normal controls - Braak 0-II). And to determine a potential detrimental role of neuronal VEGFR1 expression on AD associated pathologies, we exposed SH-SY5Y human neuroblastoma cells and mouse primary neurons to either hypoxia conditions (1%O Results: In this study, we found preferential staining of VEGFR-1 in the neuropil and neuronal cell bodies both in AD and Control hippocampus and increased VEGFR-1 immunoreactivity in dystrophic neuritic processes in the vicinity of Thio-S positive amyloid plaques in AD brains. And treatment of SH-SY5Y human neuroblastoma cell line and mouse primary neurons, with either hypoxia conditions or Aβ1-42 oligomers, resulted in increased VEGFR-1 expression and cleaved caspase 3 activation, leading to neuronal toxicities/cell death. Similarly, treatment with Aβ1-42 fibrils also increased VEGFR-1 and cleaved caspase 3 protein levels in the SH-SY5Y cells whereas treatment with Aβ1-42 monomers had no effect on VEGFR-1 expression. In addition, we show that over-expression of VEGFR-1 intracellular domains in SH-SY5Y cells directly induced neuronal toxicities and importantly, siRNA-mediated knockdown of VEGFR-1 in neurons prevented the hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril-induced toxicities and cell death phenotypes. Treatment with either hypoxia or Aβ1-42 oligomers also reduced expression of cell survival genes including VEGFR-2 and Hippo pathway YAP1 and siRNA-mediated VEGFR-1 knockdown in the neurons normalized expression of both VEGFR-2 and YAP1. Using differential gene expression analysis, we demonstrated upregulation of several inflammatory/interferon-stimulated genes (ISGs) as well as increased expression of genes involved in activation of oxidative stress and cell death pathways in response to Aβ1-42 oligomers treatment in mouse primary neurons. And siRNA-mediated VEGFR-1 knockdown in the mouse primary neurons, reduced gene expression of both the ISGs and oxidative stress/cell death pathways in response to Aβ1-42 oligomer treatment. Discussion: In summary, these results show that siRNA-mediated knockdown of VEGFR-1 in neurons significantly prevented hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril-induced cellular toxicities and cell death phenotypes, indicating a potential detrimental role of aberrant VEGFR-1 expression and signaling in response to AD associated pathologies.

Indexed as

Alzheimer’s diseaseAβ oligomers/fibrilshypoxianeuronal cell deathVEGFR-1

Identifiers

PMID42292330
PMCPMC13260607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.